Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2020 07:30 ET | Source: Biogen Inc.

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

In Phase 2 LILAC study, BIIB059 demonstrated a statistically significant reduction in joint disease activity compared to placebo in systemic lupus erythematosus patientsPositive results build on...
October 30, 2020 07:00 ET | Source: Biogen Inc.

European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and...
October 06, 2020 07:00 ET | Source: Biogen Inc.; Samsung Bioepis

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency (EMA) has...
September 14, 2020 07:30 ET | Source: Biogen Inc.

Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

After achieving carbon neutrality in 2014, Biogen further bolsters its action against climate change with the goal to become fossil fuel free by 2040 and initiates research collaborations with global...
September 11, 2020 08:01 ET | Source: Biogen Inc.

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY® (diroximel fumarate)Real-world findings evaluate quality of life benefits associated with...
September 08, 2020 07:30 ET | Source: Biogen Inc.

New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planningReal-world data from MS PATHS identifies clinically relevant...
August 07, 2020 07:30 ET | Source: Biogen Inc.

FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review

Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the...
August 06, 2020 08:02 ET | Source: Biogen Inc.; Denali Therapeutics Inc.

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement...
July 24, 2020 16:06 ET | Source: Biogen Inc.

Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced there will be multiple data presentations from its Alzheimer’s disease (AD) clinical development portfolio,...
July 21, 2020 18:00 ET | Source: Biogen Inc.

Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer

CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer,...